Semaglutide treatment had the highest SUCRA ranking in decreasing the levels of ALT and AST.<h4>Conclusion</h4>The network meta-analysis provided evidence for the efficacy of vitamin E, pioglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists in treating patients with NAFLD. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.